Not registered yet? Please contact our project manager Dr. Sara Stöber . This area is only for members of the research consortium.

Stay informed on the project!

14 November 2023

World Pancreatic Cancer Day

Today, 14th November, marks a significant day globally — World Pancreatic Cancer Day. It’s a day initiated by the World Pancreatic Cancer Coalition and dedicated to raising awareness about pancreatic cancer, an illness often diagnosed in its advanced stages and known for its low survival rates.

Key Facts:

  1. Silent Threat: Pancreatic cancer is often called a “silent” disease because its symptoms can be subtle and easily attributed to other causes. This underscores the importance of paying attention to one’s body and seeking medical attention for persistent or unusual symptoms.
  2. Low Survival Rates: Pancreatic cancer has one of the lowest survival rates among major cancers. This emphasizes the urgency of early detection and underscores the need for continued research to develop more effective treatment strategies.
  3. Risk Factors: Understanding the risk factors associated with pancreatic cancer, such as family history, smoking, and certain genetic conditions, is crucial. Lifestyle changes and regular health check-ups can contribute to early intervention.

We aim to take on the the biggest challenge in the clinical management of pancreatic cancer: the current inability to diagnose it in time. Read more on our research approach here.

31 August 2023

PANCAID Newsletter – Summer 2023

🚀Our first newsletter just hit inboxes! 📨
Missed it? We got you! Simply read it online.

Subscribe to our mailing list to receive up-to-date information on what’s happening at PANCAID!

07 September 2023

PANCAID participates in first Annual Meeting of the EU Mission Cancer Cluster “Prevention and early detection (Screening)”

Organised an hosted by cluster member LUCIA in San Sebastián and remote, Matthias Löhr gave the introductory presentation of PANCAID.


PANCAID is an international research consortium aiming to develop a minimally invasive blood test using liquid biopsy to detect pancreatic cancer to facilitate early detection of the cancer and its precursors. With 16 partners + 1 associated partner from eight countries, the project has received funding for five years to potentially revolutionize current pancreatic cancer diagnosis methods and improve patient outcomes.

Learn More

Our vision

PANCAID strives to provide a minimally invasive blood test using a comprehensive panel of liquid biopsy diagnostics (LBx) for early detection of pancreatic cancer and its precursor lesions.

Read on

Why it matters

Pancreatic cancer is a malignant neoplasm that originates in the cells of the pancreas, an organ located in the abdominal cavity behind the stomach. It is known to be one of the most aggressive and deadly types of cancer, with a high mortality rate. Pancreatic cancer is often difficult to detect in its early stages, as it tends to show minimal or no symptoms until it reaches advanced stages. This makes it challenging to diagnose and treat, and contributes to its poor prognosis.

Discover more